Fig. 4: Longitudinal transcriptomic profiling of SG tissue in the TRACTISS trial. | Nature Metabolism

Fig. 4: Longitudinal transcriptomic profiling of SG tissue in the TRACTISS trial.

From: Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution

Fig. 4

a, Schematic of the longitudinal transcriptomic study from the TRACTISS randomized clinical trial in patients with SjD, including sequential lip biopsies from patients randomized to either placebo (PBO) or rituximab (RIX) (anti-CD20 B cell depleting agent) treatment. b, Changes over time in the expression of genes for lactate transporters, metabolic enzymes downstream of lactate signalling and inflammatory mediators. Blue (placebo) and red (rituximab) lines represent the fitted negative binomial mixed-effects model with a 95% confidence interval. The P values of the week/treatment ratio interaction model are shown on top. Data from patients with SjD treated with placebo (n = 12) or rituximab (n = 8) are included.

Back to article page